Clinical trials: High Risk Cancer
Glioma
Hypofractionated IMRT With Temozolomide for HGG
To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery.
- Trial name
- NCT02082119
- Testing
- Hypofractionated IMRT
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Prostate Cancer - Recurrent
HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer
The purpose of this study is to evaluate the safety and effectiveness of combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) to the pelvis and 6 months of hormonal therapy, otherwise known as short…
- Trial name
- BEACON (NCT03553602)
- Testing
- HDR Brachytherapy + EBRT + STAD
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loyola University
Advanced/Metastatic Solid Malignancies
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies.
- Trial name
- NCT03568539
- Testing
- IBI308
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Glial Cell Tumors, Malignant Gliomas
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Currently, there are few effective treatments for the following aggressive brain tumors: glioblastoma multiforme, anaplastic astrocytoma, gliomatosis cerebri, gliosarcoma, or brainstem glioma.
- Conditions
- Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Trial name
- NCT00879437
- Testing
- Valproic acid, Bevacizumab, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Colorectal Carcinoma
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
In this study, participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator's…
- Trial name
- NCT02563002
- Testing
- mFOLFOX6, FOLFIRI, Pembrolizumab
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
GIST, Metastatic Disease
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Patients with advanced GIST are treated with imatinib. This study seeks to look at a new therapeutic agent at the time of tumor progression following treatment with 600-800 mg daily of imatinib.
- Trial name
- NCT01089595
- Testing
- Nilotinib, Nilotinib with Imatinib
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer
Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities
The purpose of this pilot clinical study is to test a methodology for using high-resolution Positron Emission Tomography (PET) imaging to guide vacuum-assisted core biopsy of breast abnormalities identified on PET.
- Trial name
- PEM-BX (NCT00606931)
- Testing
- Stereo Navigator Accessory to PEM Flex PET Scanner
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Naviscan PET Systems
Prostate Cancer
Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
There is great need for improved preoperative imaging in men with high-risk prostate cancer. Investigators propose to develop and validate an optimized simultaneous PET/MRI protocol for local, regional and whole body preoperative…
- Trial name
- NCT03264456
- Testing
- [18F] Fluciclovine PET/MRI, [18F] fluciclovine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Alabama at Birmingham
Ovarian Cancer, Fallopian Tube Cancer
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT03585764
- Testing
- MOv19-BBz CAR T cells, Alpha Folate Receptor expression test
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Pennsylvania
Advanced Non-Small Cell Lung Carcinoma
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose…
- Trial name
- NCT03430063
- Testing
- SDREGN2810, SDREGN2810/ipi, HDREGN2810
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
Leiomyosarcoma
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
The purpose of this study is to learn about the safety and effects of the study medicine (called Ontorpacept or TTI-621) when given alone and when given in combination with doxorubicin for people with leiomyosarcoma.
- Trial name
- TTI-621-03 (NCT04996004)
- Testing
- Ontorpacept (TTI-621), Doxorubicin
- Where
- 23 sites in United States
- Volunteers
- 76 people
- Sponsor
- Pfizer
Carcinoma, Hepatocellular
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
This study aims to compare the role of peginterferon α-2b (50 μg/week) vs. control (no treatment) in the prevention of hepatocellular carcinoma, in adult patients with cirrhosis and initial signs of portal hypertension who did…
- Trial name
- NCT00759109
- Testing
- Peginterferon alfa-2b, Observation (no treatment)
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Glioblastoma (GBM) is the most common malignant brain tumor among adults. As the diagnosis is generally considered terminal, patients with GBM often suffer from anxiety and other comorbid conditions, including depression, pain…
- Trial name
- NCT05753007
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mclean Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
The main purpose of this study is to see if the combination of ofatumumab with high dose methylprednisolone followed by additional treatment with ofatumumab and lenalidomide can help people with relapsed or refractory CLL/SLL get…
- Trial name
- NCT01497496
- Testing
- High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
Certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and other agents. There is a factor called ISG15 which might help doctors better identify patients with advanced non-small cell lung cancer…
- Trial name
- NCT01607554
- Testing
- Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- New Mexico Cancer Research Alliance
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Breast Cancer
Protocol for Women at Increased Risk of Developing Breast Cancer
To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.
- Trial name
- NCT00291694
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Endometrial Adenocarcinoma, Stage IA Uterine Corpus Cancer
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
This phase II trial studies how well radiation therapy, paclitaxel, and carboplatin work in treating patients with high-risk endometrial cancer. Radiation therapy uses high energy x rays to kill tumor cells.
- Conditions
- Endometrial Adenocarcinoma, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
- Trial name
- NCT01041027
- Testing
- Paclitaxel, Carboplatin, Internal Radiation Therapy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Albert Einstein College of Medicine
Metastatic Melanoma
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.
- Trial name
- PROCLIVITY02 (NCT01856023)
- Testing
- High Dose Interleukin-2, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clinigen, Inc.
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come…
- Conditions
- Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma
- Trial name
- NCT02192359
- Testing
- Carboxylesterase-expressing Allogeneic Neural Stem Cells, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.